GlassScriptPhysician profile
Alif Manejwala
NPI 1679681902
$4,104.88
in general payments reported to CMS, 2019-2025
31 companies · $325 in 2025
The $325 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $552 · 2021: $887 · 2022: $773 · 2023: $498 · 2024: $679 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.85 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.86 | 2019-2025 | |
| Celgene Corporation | $408.25 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $397.19 | 2019-2024 | |
| Braintree Laboratories, INC. | $358.91 | 2019-2022 | |
| Qol Medical, LLC | $265.10 | 2019-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $200.51 | 2020-2023 | Mounjaro, Trulicity |
| Ardelyx, INC. | $190.38 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $165.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.65 | 2019-2023 | Trulance |
| Janssen Biotech, INC. | $149.76 | 2022-2025 | Tremfya, Simponi, Stelara |
| Astellas Pharma US INC | $128.52 | 2024 | Veozah |
| Allergan, INC. | $108.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.64 | 2022 | |
| Novo Nordisk INC | $65.76 | 2021 | |
| Ironwood Pharmaceuticals, INC | $62.79 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.08 | 2021-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $55.44 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $49.77 | 2019-2020 | |
| Genzyme Corporation | $48.51 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $41.33 | 2021 | |
| Ferring Pharmaceuticals INC. | $36.99 | 2019-2022 | |
| Pfizer INC. | $34.16 | 2022-2025 | |
| Amgen INC. | $27.29 | 2024 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $19.72 | 2021 | |
| Alfasigma USA, INC. | $17.87 | 2020 | |
| Organon LLC | $17.48 | 2023 | Renflexis, Hadlima |
| Medtronic, INC. | $17.17 | 2021 | |
| Grifols USA, LLC | $16.87 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.20 | 2023 | Voquezna |
| Phadia US INC. | $11.66 | 2019 | |
| Travere Therapeutics, INC. | $1.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alif Manejwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.